Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis

被引:130
作者
Du Sean Quan [1 ]
Yuan Weiming [1 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, 1450 Biggy St,NRT5516, Los Angeles, CA 90033 USA
关键词
adaptive immunity; antiviral drugs; COVID-19; innate immunity; SARS-CoV-2; target cell-limited model; INFLUENZA; DYNAMICS; CORONAVIRUS; OUTBREAK; PROTEIN; WUHAN; SARS; DRUG; H5N1;
D O I
10.1002/jmv.25866
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have applied mathematical modeling to investigate the infections of the ongoing coronavirus disease-2019 (COVID-19) pandemic caused by SARS-CoV-2 virus. We first validated our model using the well-studied influenza viruses and then compared the pathogenesis processes between the two viruses. The interaction between host innate and adaptive immune responses was found to be a potential cause for the higher severity and mortality in COVID-19 patients. Specifically, the timing mismatch between the two immune responses has a major impact on disease progression. The adaptive immune response of the COVID-19 patients is more likely to come before the peak of viral load, while the opposite is true for influenza patients. This difference in timing causes delayed depletion of vulnerable epithelial cells in the lungs in COVID-19 patients while enhancing viral clearance in influenza patients. Stronger adaptive immunity in COVID-19 patients can potentially lead to longer recovery time and more severe secondary complications. Based on our analysis, delaying the onset of adaptive immune responses during the early phase of infections may be a potential treatment option for high-risk COVID-19 patients. Suppressing the adaptive immune response temporarily and avoiding its interference with the innate immune response may allow the innate immunity to more efficiently clear the virus.
引用
收藏
页码:1615 / 1628
页数:14
相关论文
共 35 条
[1]   Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020 [J].
Backer, Jantien A. ;
Klinkenberg, Don ;
Wallinga, Jacco .
EUROSURVEILLANCE, 2020, 25 (05) :10-15
[2]  
BEAUCHEMIN CAA, 2011, BMC PUBLIC HEALTH S1, V11
[3]   Virus dynamics and drug therapy [J].
Bonhoeffer, S ;
May, RM ;
Shaw, GM ;
Nowak, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6971-6976
[4]   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].
Chen, Nanshan ;
Zhou, Min ;
Dong, Xuan ;
Qu, Jieming ;
Gong, Fengyun ;
Han, Yang ;
Qiu, Yang ;
Wang, Jingli ;
Liu, Ying ;
Wei, Yuan ;
Xia, Jia'an ;
Yu, Ting ;
Zhang, Xinxin ;
Zhang, Li .
LANCET, 2020, 395 (10223) :507-513
[5]   Influenza and the challenge for immunology [J].
Doherty, PC ;
Turner, SJ ;
Webby, RG ;
Thomas, PG .
NATURE IMMUNOLOGY, 2006, 7 (05) :449-455
[6]   Anatomical and Histological Factors Affecting Intranasal Drug and Vaccine Delivery [J].
Gizurarson, Sveinbjorn .
CURRENT DRUG DELIVERY, 2012, 9 (06) :566-582
[7]   Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis [J].
Hamming, I ;
Timens, W ;
Bulthuis, MLC ;
Lely, AT ;
Navis, GJ ;
van Goor, H .
JOURNAL OF PATHOLOGY, 2004, 203 (02) :631-637
[8]   Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (vol 395, pg 497, 2020) [J].
Huang, C. ;
Wang, Y. ;
Li, X. .
LANCET, 2020, 395 (10223) :496-496
[9]  
Janeway CA, 2001, Immunobiology: the immune system in health and disease, V5th
[10]  
LEVY M, 2008, BERNE LEVY PHYSL